BELLUS Health Reports Second Quarter 2020 Financial Results and Business Highlights

LAVAL, Quebec–(BUSINESS WIRE)–BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (BELLUS Health or the Company), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today reported its financial and operating results for the second quarter ended June 30, 2020.
Announced topline results from the Phase 2 RELIEF clinical trial of BLU-5937 in patients with refractory chro…

Click here to view the original article.